Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Baltimore, MD
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Rockville, MD
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Rockville, MD
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Worcester, MA
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Worcester, MA
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Boston, MA
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Edina, MN
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Edina, MN
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Minneapolis, MN
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Lebanon, NH
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Manchester, NH
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Manchester, NH
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Charleston, SC
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Charleston, SC
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Bristol, TN
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Bristol, TN
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Bedford, TX
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Bedford, TX
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Dallas, TX
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Dallas, TX
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated:  3/27/2013
Clinical Research Facility
mi
from
Houston, TX
A Phase II Trial of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in Participants With Breast Cancer (MK-8669-064 AM2)
A Phase II Randomized Trial of the Combination of Ridaforolimus and Exemestane, Compared to Ridaforolimus, Dalotuzumab and Exemestane in High Proliferation, Estrogen Receptor Positive Breast Cancer Patients
Status: Enrolling
Updated: 3/27/2013
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)
Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk
Status: Enrolling
Updated:  4/17/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Using Technology to Improve Physical Activity Levels Among Postmenopausal Women (The Active & Aware Study)
Using Technology to Promote Activity in Women at Elevated Breast Cancer Risk
Status: Enrolling
Updated: 4/17/2013
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Exercise in Breast Cancer Survivors
Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile
Status: Enrolling
Updated:  4/22/2013
University of Mississippi Health Care
mi
from
Jackson, MS
Exercise in Breast Cancer Survivors
Exercise in Breast Cancer Survivors: Analysis of Angiogenic Profile
Status: Enrolling
Updated: 4/22/2013
University of Mississippi Health Care
mi
from
Jackson, MS
Click here to add this to my saved trials
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated:  5/8/2013
University of Chicago Medical Center University of Chicago (16)
mi
from
Chicago, IL
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated: 5/8/2013
University of Chicago Medical Center University of Chicago (16)
mi
from
Chicago, IL
Click here to add this to my saved trials
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated:  5/8/2013
Massachusetts General Hospital SC-5
mi
from
Boston, MA
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated: 5/8/2013
Massachusetts General Hospital SC-5
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated:  5/8/2013
MD Anderson Cancer Center/University of Texas UT/MD
mi
from
Houston, TX
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated: 5/8/2013
MD Anderson Cancer Center/University of Texas UT/MD
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated:  5/8/2013
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
A Phase I Study of LJM716 in Squamous Cell Carcinoma of Head and Neck, or HER2+ Breast Cancer or Gastric Cancer
A Phase I Study of LJM716 in Patients With Squamous Cell Carcinoma of Head and Neck, or HER2 Overexpressing Metastatic Breast Cancer or Gastric Cancer
Status: Enrolling
Updated: 5/8/2013
University of Utah / Huntsman Cancer Institute Huntsman
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  5/16/2013
Ironwood Cancer and Research Centers Ironwood
mi
from
Chandler, AZ
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 5/16/2013
Ironwood Cancer and Research Centers Ironwood
mi
from
Chandler, AZ
Click here to add this to my saved trials
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  5/16/2013
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 5/16/2013
Highlands Oncology Group, P.A.
mi
from
Fayetteville, AR
Click here to add this to my saved trials
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  5/16/2013
Texas Oncology, P.A. Dept.ofTexas Oncology, PA
mi
from
Dallas, TX
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 5/16/2013
Texas Oncology, P.A. Dept.ofTexas Oncology, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated:  5/16/2013
US Oncology Central Monitoring
mi
from
Dallas, TX
Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer
A Dose-finding Phase Ib Study Followed by an Open-label, Randomized Phase II Study of BEZ235 Plus Paclitaxel in Patients With HER2 Negative, Inoperable Locally Advanced or Metastatic Breast Cancer
Status: Enrolling
Updated: 5/16/2013
US Oncology Central Monitoring
mi
from
Dallas, TX
Click here to add this to my saved trials
Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty
Neurocognitive Impairment in Women With Early Stage Breast Cancer
Status: Enrolling
Updated:  5/16/2013
Virnigia Commonwealth University
mi
from
Richmond, VA
Examining a Common Complaint of Women Who Receive Chemotherapy for Breast Cancer- Cognitive Difficulty
Neurocognitive Impairment in Women With Early Stage Breast Cancer
Status: Enrolling
Updated: 5/16/2013
Virnigia Commonwealth University
mi
from
Richmond, VA
Click here to add this to my saved trials
Role of Beta-Endorphin in Cancer Therapy Fatigue
Beta-Endorphin as a Mediator of Cancer Therapy-Induced Fatigue
Status: Enrolling
Updated:  5/21/2013
Massachusetts General Hospital
mi
from
Boston, MA
Role of Beta-Endorphin in Cancer Therapy Fatigue
Beta-Endorphin as a Mediator of Cancer Therapy-Induced Fatigue
Status: Enrolling
Updated: 5/21/2013
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
Intellectual Impairment in Women With Breast Cancer
Assessment and Treatment of Cognitive Deficits in Breast Cancer
Status: Enrolling
Updated:  5/28/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Intellectual Impairment in Women With Breast Cancer
Assessment and Treatment of Cognitive Deficits in Breast Cancer
Status: Enrolling
Updated: 5/28/2013
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates
Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital
Status: Enrolling
Updated:  5/30/2013
Summa Akron City Hospital
mi
from
Akron, OH
Impact of Breast Magnetic Resonance Imaging (MRI) on Mastectomy Rates
Evaluation of Breast Magnetic Resonance Imaging (MRI) Impact on Mastectomy Rate at Summa Akron City Hospital
Status: Enrolling
Updated: 5/30/2013
Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  6/4/2013
Swedish Cancer Institute
mi
from
Seattle, WA
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 6/4/2013
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated:  6/4/2013
Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center
mi
from
Seattle, WA
Pre-Surgery Positron Emission Mammography in Patients With Newly Diagnosed Breast Cancer
Clinical Value of Pre-Surgery Positron Emission Mammography (PEM) in Patients With Newly Diagnosed Breast Cancer
Status: Enrolling
Updated: 6/4/2013
Swedish Cancer Institute Cherry Hill Campus - Comprehensive Breast Center
mi
from
Seattle, WA
Click here to add this to my saved trials
Participation Restrictions in Breast Cancer Survivors
Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors
Status: Enrolling
Updated:  6/6/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Participation Restrictions in Breast Cancer Survivors
Participation Restrictions in Young-Middle Adult Rural Breast Cancer Survivors
Status: Enrolling
Updated: 6/6/2013
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
Status: Enrolling
Updated:  7/2/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Dose Dense TC + Pegfilgrastim Support for Breast Cancer
Phase II Study of Dose-Dense TC (Docetaxel + Cyclophosphamide) With Pegfilgrastim Support for Adjuvant Therapy of pN0, pN1 or Nx Breast Cancer
Status: Enrolling
Updated: 7/2/2013
University of Wisconsin Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen
Status: Enrolling
Updated:  7/5/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Loss of Grip Strength, BMI, and Adjuvant Endocrine Therapy Breast Cancer
A Prospective Assessment of Loss of Grip Strength by Baseline BMI in Breast Cancer Patients Receiving Adjuvant Third-generation Aromatase Inhibitors and Tamoxifen
Status: Enrolling
Updated: 7/5/2013
University of Michigan Comprehensive Cancer Center
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Status: Enrolling
Updated:  7/16/2013
Providence Portland Medical Center
mi
from
Portland, OR
Stereotactic Radiation and OX40 in Patients With Breast Cancer Metastatic to the Liver or Lung
Phase I/II Study of Stereotactic Body Radiation Therapy to Metastatic Lesions in the Liver or Lung in Combination With Monoclonal Antibody to OX40 in Patients With Progressive Metastatic Breast Cancer After Systemic Therapy.
Status: Enrolling
Updated: 7/16/2013
Providence Portland Medical Center
mi
from
Portland, OR
Click here to add this to my saved trials
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated:  7/30/2013
University of South Florida
mi
from
Tampa, FL
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated: 7/30/2013
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated:  7/30/2013
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated: 7/30/2013
Moffitt Cancer Center and Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated:  7/30/2013
Carol and Frank Morsani Center for Advanced Healthcare
mi
from
Tampa, FL
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Mindfulness-Based Stress Reduction (MBSR) Symptom Cluster Trial for Breast Cancer Survivors
Status: Enrolling
Updated: 7/30/2013
Carol and Frank Morsani Center for Advanced Healthcare
mi
from
Tampa, FL
Click here to add this to my saved trials
The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors
The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors
Status: Enrolling
Updated:  7/31/2013
Texas Tech University Health Sciences Center
mi
from
Amarillo, TX
The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors
The Change Cycle Intervention for Improving Quality of Life in Breast Cancer Survivors
Status: Enrolling
Updated: 7/31/2013
Texas Tech University Health Sciences Center
mi
from
Amarillo, TX
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Birmingham, AL
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Anchorage, AK
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Anchorage, AK
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Phoenix, AZ
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Fort Smith, AR
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Fort Smith, AR
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Santa Clara, CA
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Aurora, CO
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Bridgeport, CT
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Bridgeport, CT
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Newark, DE
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Newark, DE
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Daytona Beach, FL
Click here to add this to my saved trials
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated:  8/19/2013
Clinical Research Facility
mi
from
Decatur, GA
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite)
An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Non-Squamous Non-Small Cell Lung Cancer, Recurrent Glioblastoma, or Metastatic Renal Cell Cancer Treated With Avastin
Status: Enrolling
Updated: 8/19/2013
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials